CASI Raises $50 Million to Launch Drugs in China

CASI Pharma, a Maryland-Beijing company, announced a $50 million private placement, which it will use to launch its first commercial product in China and supply working capital. Two months ago, CASI acquired a portfolio of 29 generic drug candidates from Sandoz, the generic drug division of Novartis. CASI plans to select certain members of the portfolio to develop for China approval. More details.... Stock Symbols: (NSDQ: CASI) (NYSE: NVS) Share this with colleagues: // //